Injectable polypeptide/chitosan hydrogel with loaded stem cells and rapid gelation promoting angiogenesis for diabetic wound healing.
Xing. Cencan C; Hou. Liangxuan L; Sun. Chunbin C; Chen. Hongyu H; Li. Yingxian Y; Li. Luping L; Wu. Yawen Y; Li. Liang L; An. Heng H; Wen. Yongqiang Y; Du. Hongwu H
Key Findings
- Pal‑7‑chitosan hydrogel (CP7) gels quickly, is strong, biocompatible, and kills bacteria.
- Loading human deciduous‑tooth stem cells (SHED) into the gel boosts blood‑vessel formation and pushes immune cells toward a healing (M2) state.
- In diabetic mouse wounds, SHED@CP7 achieved >95% closure, cut inflammatory markers (TNF‑α, IL‑6) by ~75‑80%, raised anti‑inflammatory IL‑10 by ~58%, and increased CD31‑positive vessels by 69%.
Practical Outcomes
- For DIY health enthusiasts, the study shows that Pal‑7 can help create a fast‑gelling, antibacterial wound‑cover that supports healing, but it currently requires specialized materials (chitosan, glutaraldehyde cross‑linker) and stem cells, limiting home use. The concept may inspire future over‑the‑counter dressings, yet at present it isn’t a ready‑to‑apply protocol for personal use.
Summary
Scientists made a gel that mixes a skin‑friendly peptide (Pal‑7) with chitosan and stem cells from baby teeth. When they put this gel on wounds in diabetic mice, the cuts healed faster, with less inflammation and more new blood vessels.
Abstract
Diabetic wounds face challenges like infection, prolonged inflammation, and poor vascularization. To address these, we developed an injectable hydrogel for diabetic wound dressing by grafting palmitoyl tetrapeptide-7 (Pal-7) onto chitosan (CS) to form CS/Pal-7 (CP7). Glutaraldehyde (GA) was used to enhance crosslinking between CS, creating the CP7 hydrogel. The hydrogel showed rapid gelation, good mechanical properties, biocompatibility, and strong antibacterial effects. Additionally, stem cells derived from human deciduous teeth (SHED) were loaded into the CP7 hydrogel to form SHED@CP7. This complex promoted human umbilical vein endothelial cell (HUVEC) migration and tube formation, aiding angiogenesis, and induced macrophage polarization toward the M2 phenotype, exerting anti-inflammatory effects. In streptozotocin-induced diabetic mouse wounds, SHED@CP7 significantly improved wound healing with over 95 % wound closure, increased collagen deposition, and reduced tumor necrosis factor-α (TNF-α) expression by approximately 75 % and Interleukin-6 (IL-6) expression by around 81 %. It also increased Interleukin-10 (IL-10) expression by approximately 58 %, modulating the inflammatory microenvironment for regeneration. Moreover, SHED@CP7 enhanced angiogenesis, as shown by a 69 % increase in endothelial cell marker CD31 staining, supporting faster wound healing. These results highlight the potential of SHED@CP7 as an effective treatment for diabetic wounds.
Study Information
pubmed
2025
2025-02-27T00:00:00.000Z
10.1016/j.ijbiomac.2025.141578
2
79